Skip to main content
SpringerLink
Log in

Locoregional Therapies in the Management of Hepatocellular Carcinoma

  • Chapter
  • First Online:
Book cover Primary and Metastatic Liver Tumors

  • 621 Accesses

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy in the world, with over 14 million cases in 2012 and an expected growth to 22 million over the next 20 years [1–3]. It develops secondary to intrinsic liver diseases such as viral hepatitis, alcoholic cirrhosis, steatohepatitis, biliary cirrhosis, or other rarer causes. It represents the third most common etiology of cancer-related deaths in the world and the seventh most common etiology in the United States [3, 4]. As most patients have concomitant chronic liver disease leading to the development of HCC, management of the disease becomes more complicated. Staging and treatment options are impacted not only by the extent of the tumor but also by the patient’s liver function and performance status. Because the majority of patients present with unresectable disease, locoregional therapies, including image-guided percutaneous ablation and image-guided transcatheter tumor therapies, play an important role in the management of patients with HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stuver S, Trichopoulos D. Cancer of the liver and biliary tract. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology. 2nd ed. New York: Oxford University Press; 2008.

    Google Scholar 

  2. Stewart BW, Wild CP, editors. World cancer report 2014. Lyon, France: International Agency for Research on Cancer; 2014.

    Google Scholar 

  3. Ghouri YA, Milan I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.

    Article  CAS  Google Scholar 

  4. World Health Organization, International Agency for Research on Cancer. Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://www.globocan.iarc.fr/PAges/fact_sheets_population.aspx.

  5. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38.

    Article  CAS  Google Scholar 

  6. Llovet JM, et al. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1990;30:1434–40.

    Article  Google Scholar 

  7. Yao FY, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873–83.

    Article  Google Scholar 

  8. Lesurtel M, et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transpl. 2006;6:2644–50.

    Article  CAS  Google Scholar 

  9. Heckman JT, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Onc. 2008;15(11):3169–77.

    Article  Google Scholar 

  10. Yao FT, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005;11(12):1505–14.

    Article  Google Scholar 

  11. Yao FT, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968–77.

    Article  Google Scholar 

  12. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G, SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.

    Article  CAS  Google Scholar 

  13. Scudamore CH, et al. Liver tumor ablation techniques. J Investig Surg. 1997;10(4):157–64.

    Article  CAS  Google Scholar 

  14. Padma S, et al. Liver tumor ablation: percutaneous and open approaches. J Surg Oncol. 2009;100(8):619–34.

    Article  Google Scholar 

  15. Chen HW, et al. Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. Int J Surg. 2011;9(2):188–91.

    Article  CAS  Google Scholar 

  16. McCarley JR, Soulen MC. Percutaneous ablation of hepatic tumors. Semin Intervent Radiol. 2010;27(3):255–60.

    Article  Google Scholar 

  17. Bilchik AJ, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg. 2000;135(6):657–62; discussion 662–4.

    Article  CAS  Google Scholar 

  18. Molla N, et al. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol. 2014;21(3):e480–92.

    Article  CAS  Google Scholar 

  19. Chen MS, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–8.

    Article  Google Scholar 

  20. Lubner MG, et al. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol. 2010;21(8 Suppl):S192–203.

    Article  Google Scholar 

  21. Santambrogio R, et al. Comparison of laparoscopic microwave to radiofrequency ablation of small hepatocellular carcinoma (</=3 cm). Ann Surg Oncol. 2017;24(1):257–63.

    Article  Google Scholar 

  22. Jaskolka JD, et al. Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol. 2005;16(4):485–91.

    Article  Google Scholar 

  23. Gervais DA, et al. Society of interventional radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol. 2009;20(7 Suppl):S342–7.

    Article  Google Scholar 

  24. Zhi-Yu H, et al. A clinical study of thermal monitoring techniques of ultrasound-guided microwave ablation for hepatocellular carcinoma in high-risk locations. Sci Rep. 2017;7:41246.

    Article  Google Scholar 

  25. Rempp H, et al. The current role of minimally invasive therapies in the management of liver tumors. Abdom Imaging. 2011;36(6):635–47.

    Article  Google Scholar 

  26. Cannon R, et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–9.

    Article  Google Scholar 

  27. Thompson KR, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611–21.

    Article  Google Scholar 

  28. Feng K, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802.

    Article  Google Scholar 

  29. Lu DS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology. 2005;234(3):954–60.

    Article  Google Scholar 

  30. Salmi A, et al. Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. Int J Med Sci. 2008;5(6):327–32.

    Article  Google Scholar 

  31. Graf D, et al. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25(5):430–7.

    Article  Google Scholar 

  32. Sheth RA, et al. Role of locoregional therapy and predictors for dropout in patients with hepatocellular carcinoma listed for liver transplantation. J Vasc Interv Radiol. 2015;26(12):1761–8. quiz 1768.

    Article  Google Scholar 

  33. Ravaioli M, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant. 2008;8(12):2547–57.

    Article  CAS  Google Scholar 

  34. Hasegawa K, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49(4):589–94.

    Article  Google Scholar 

  35. Huang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–12.

    Article  Google Scholar 

  36. Vasnani R, et al. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation. Hepatobiliary Surg Nutr. 2016;5(3):225–33.

    Article  Google Scholar 

  37. Peng Z-W, Zhang Y-J, Chen M-S, Xu L, Liang H-H, Lin X-J, Guo R-P, Zhang Y-Q, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426–32.

    Article  Google Scholar 

  38. Bholee AK, et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol. 2017;19(7):844–52.

    Article  CAS  Google Scholar 

  39. Wheeler G, Melia W, Dubbins P, Jones B, Nunnerley H, Johnson P, et al. Non-operative arterial embolization in primary liver tumours. Br Med J. 1979;ii:242–4.

    Article  Google Scholar 

  40. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J, Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.

    Article  Google Scholar 

  41. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71.

    Article  CAS  Google Scholar 

  42. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987;163(2):345–51.

    Article  CAS  Google Scholar 

  43. Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Intervent Radiol. 2011;28(2):207–11.

    Article  Google Scholar 

  44. Lammer J, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of HCC: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.

    Article  Google Scholar 

  45. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F, Precision Italia Study Group. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64.

    Article  CAS  Google Scholar 

  46. Nasser F, Cavalcante RN, Galastri FL, de Rezende MB, Felga GG, Travassos FB, De Fina B, Affonso BB. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. J Vasc Interv Radiol. 2014;25(7):1012–7.

    Article  Google Scholar 

  47. Ward TJ, et al. Management of high hepatopulmonary shunting in patients undergoing hepatic radioembolization. J Vasc Interv Radiol. 2015;26(12):1751–60.

    Article  Google Scholar 

  48. Young L, et al. Hepatopulmonary shunt reduction using external beam radiation therapy prior to yttrium-90 radioembolization of HCC. J Vasc Interv Radiol. 2017;28(2):S76.

    Article  Google Scholar 

  49. Sandow T, et al. Elevated lung shunt fraction as a prognostic indicator for disease progression and metastasis in hepatocellular carcinoma. J Vasc Interv Radiol. 2016;27(6):804–11.

    Article  Google Scholar 

  50. Morshedi MM, Bauman M, Rose SC, Kikolski SG. Yttrium-90 resin microsphere radioembolization using an antireflux catheter: an alternative to traditional coil embolization for nontarget protection. Cardiovasc Interv Radiol. 2015;38(2):381–8.

    Article  Google Scholar 

  51. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Gaba RC, Mulcahy MF, Baker T, Sato K, Hickey R, Ganger D, Riaz A, Fryer J, Caicedo JC, Abecassis M, Kulik L, Salem R. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029–36.

    Article  Google Scholar 

  52. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192–201.

    Article  Google Scholar 

  53. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller F, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–1163.e2.

    Article  Google Scholar 

  54. Arepally A et al. Society of interventional radiology annual meeting, Washington, DC; 2017.

    Google Scholar 

  55. Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34(17):2046–53.

    Article  CAS  Google Scholar 

  56. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826–37.

    Article  CAS  Google Scholar 

  57. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.

    Article  CAS  Google Scholar 

  58. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.

    Article  Google Scholar 

  59. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G, SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.

    Article  CAS  Google Scholar 

  60. Fidelman N, Kerlan RK Jr. Transarterial chemoembolization and (90)Y radioembolization for hepatocellular carcinoma: review of current applications beyond intermediate-stage disease. AJR Am J Roentgenol. 2015;205(4):742–52.

    Article  Google Scholar 

  61. Kokabi N, Duszak R, Xing M, et al. Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. Future Oncol. 2017;13(24):2021–33.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Division of Interventional Radiology and Image-Guided Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Alexa O. Levey, R. Mitch Ermentrout & Zachary L. Bercu

  2. Piedmont South Imaging, Newnan, GA, USA

    Darren D. Kies

Authors
  1. Alexa O. Levey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Mitch Ermentrout
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zachary L. Bercu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Darren D. Kies
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Darren D. Kies .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Winship Cancer Institute, Emory University Hospital Midtown, Atlanta, GA, USA

    Kenneth Cardona

  2. Division of Surgical Oncology, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, USA

    Shishir K. Maithel

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Levey, A.O., Ermentrout, R.M., Bercu, Z.L., Kies, D.D. (2018). Locoregional Therapies in the Management of Hepatocellular Carcinoma. In: Cardona, K., Maithel, S. (eds) Primary and Metastatic Liver Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-91977-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91977-5_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91976-8

  • Online ISBN: 978-3-319-91977-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation